Annita Kolnagou
Publications by Year
Research Areas
Hemoglobinopathies and Related Disorders, Iron Metabolism and Disorders, Pharmacological Effects and Toxicity Studies, Trace Elements in Health, Erythrocyte Function and Pathophysiology
Most-Cited Works
- → Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations(2005)125 cited
- → Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)(2000)117 cited
- → Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions(2003)110 cited
- → Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications(2020)97 cited
- → The Role of Iron and Chelators on Infections in Iron Overload and Non Iron Loaded Conditions: Prospects for the Design of New Antimicrobial Therapies(2010)88 cited
- → Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2*(2006)79 cited
- → Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology(2015)68 cited
- → Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases(2010)62 cited
- → Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*(2012)59 cited
- → Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols(2008)52 cited